Epidermal lipids: Thermotropic behavior and role in transcutaneous permeation of levodopa

Drug Development Research

Volumn 63, Issue 4, 2004, Pages 190-199

  Babita, Kumar ^a   Rana, Vikas ^b   Tiwary, Ashok Kumar ^a  

^a PUNJABI UNIVERSITY   (India)

^b Govt Polytechnic for Women   (India)

Author keywords

Differential scanning calorimetry; Epidermal cholesterol; Levodopa; Sphingosine; Triglycerides

Indexed keywords

3 CHLOROALANINE; ALCOHOL; ANTILIPEMIC AGENT; ATORVASTATIN; CARBIDOPA; CERAMIDE; CERULENIN; CHOLESTEROL; FATTY ACID; LEVODOPA; SKIN LIPID; SPHINGOSINE; TRIACYLGLYCEROL;

ANIMAL TISSUE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DOSE RESPONSE; DRUG PENETRATION; ENTHALPY; EPIDERMIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIPID COMPOSITION; LIPID ENDOTHERMIC TRANSITION; LIPID SYNTHESIS INHIBITION; LIPOGENESIS; MALE; NONHUMAN; PERMEABILITY BARRIER; RAT; SKIN PERMEABILITY; THERMODYNAMICS; THERMOTROPIC ACTIVITY;

EID: 16344390428     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10413     Document Type: Article

References (26)

1. Babita, Gupta S, Tiwary AK. 2002. Role of sphingosine synthesis inhibition in transcutaneous delivery of levodopa. Int J Pharm 238:43-50.
2. Barry BW. 1987. Mode of action of penetration enhancers in human skin. J Control Release 6:85-97.
3. Behne M, Uchida Y, Seki T, Ortiz de Montellano P, Elias PM, Holleran WM. 2000. Omega-hydroxyceramide are required for corneocyte lipid envelope formation and normal epidermal permeability barrier function. J Invest Dermatol 114:185-192.
4. Bouwstra JA, Peschier LJC, Brussee J, Bodde HE. 1989. Effect of n-alkyl azocycloheptan-2-ones including azones on the thermal behaviour of human stratum corneum. Int J Pharm 2:47-54.
5. Bouwstra JA, Cooris GS, Salomons-de Vries MA, van der Spek JA, Bras W. 1992. Structure of human stratum corneum as a function of temperature and hydration: a wide angle X-ray diffraction study. Int J Pharm 84:205-216.
6. Cornwell PA, Barry BW, Bouwstra JA, Gooris GS. 1996. Mode of action of terpene penetration enhancers in human skin; differential scanning calorimetry, small X-ray diffraction and enhancer uptake studies. Int J Pharm 127:9-26.
7. Elias PM, Menon GK. 1991. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 24:1-26.
8. Feingold KR. 1991. The regulation and role of lipid synthesis. Adv Lipid Res 24:57-82.
9. Feingold KR, Mao-Qiang M, Menon GK, Cho SS, Brown BE, Elias PM. 1990. Cholesterol synthesis is required for cutaneous barrier function in mice. J Clin Invest 86:1738-1745.
10. Gamez R, Hagel RB, MacMullan EA. 1976. Analytical profile of levodopa. Analytical Profile of Drug Substance 5:189-223.
11. Ghanem AH, Mahmoud H, Higuchi WI, Liu P, Good WR. 1992. The effects of ethanol transport of lipophilic and polar permeants across hairless mouse skin: methods/validation of a novel approach. Int J Pharm 78:137-156.
12. Golden GM, Guzek DB, Harris RR, McKie JE, Potts RO. 1986. Lipid thermotropic transitions in human stratum corneum. J Clin Invest 86:255-259
13. Gupta M, Mahajan A, Babita, Gupta S, Tiwary AK. 2003. Inhibition of skin sphingosine synthesis: enhanced percutaneous permeation of 5-fluorouracil. Pharmazie 59:212-216.
14. Halvorson DL, McCune SA. 1984. Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid. Lipids 19:851-856.
15. Harder S, Bass H, Rietbrock S. 1995. Concentration effect relationship of levodopa in patients with Parkinsons disease. Clin Pharmacokinet 29:243-256.
16. Holleran WM, Feingold KR, Mao-Quing M, Gao WN, Lee JM, Elias PM. 1991a. Regulation of epidermal sphingolipid synthesis by permeability barrier function. J Lipid Res 32:1151-1158.
17. Holleran WM, Mao-Quing M, Gao WN, Menon GK, Elias PM. 1991b. Sphingolipid are required tor mammalian epidermal barrier function: Inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation. J Clin Invest 88:1338-1345.
18. Krill SL, Knutson K, Higuchi WI. 1992. Ethanol effects on the stratum corneum lipid phase behaviour. Biochim Biophys Acta 112:273-280.
19. Leopold SC, Lippold CB. 1995. An attempt to clarify the mechanism of penetration enhancing effect of lipophilic vehicles with differential scanning calorimetry (DSC). J Pharm Pharmacol 47:276-281.
20. Medlock KA, Merrill AH. 1988. Inhibition of serine palmitoyl-transferase in vitro and long chain base biosynthesis in intact Chinese hamster ovary cell by beta chloroalanine. Biochem 27:7079-7084.
21. Ottey KA, Wood LC, Grunfeld C, Elias PM, Feingold KR. 1995. Cutaneous permeability barrier disruption increases fatty acid synthesis enzyme activity in the epidermis of hairless mice. J Invest Dermatol 104:401-404.
22. Phillips BB. 1997. Atorvastatin: a review of its pharmacology and place in therapy. Am J Cardiol 80:39-44.
23. Robertson DRC, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, George CF. 1989. The effects of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 28:61-69.
24. Thupari JN, Finn ML, Kuhajda FP. 2001. Fatty acid synthase inhibition in human breast cancer cells leads to Malonyl CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285:217-223.
25. Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM. 1996. Metabolic approaches to enhance transdermal drug delivery. I. Effect of lipid synthesis inhibitors. J Pharm Sci 85:643-648.
26. Vance D, Goldberg I, Mitsuhashi O, Bloch K. 1972. Inhibition of fatty acid synthetases by the antibiotic cerulenin. Biochem Biophys Res Commun 48:649-656.